Thrombolytic therapy for deep vein thrombosis: potential application of plasmin

Thrombosis Research

Volumn 123, Issue SUPPL. 4, 2009, Pages

  Marder, Victor J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Deep vein thrombosis (DVT); Hemostatic safety; Plasmin

Indexed keywords

FIBRINOGEN; PLASMIN; PLASMINOGEN ACTIVATOR; TAL 0500018; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DELIVERY SYSTEM; FIBRINOLYTIC THERAPY; HEMOSTASIS; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INFUSIONS, INTRA-ARTERIAL; PLASMIN; RABBITS; RISK ASSESSMENT; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 62349083666     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(09)70145-8     Document Type: Article

References (42)

1. Konstantinides S., and Marder V.J. Thrombolysis in venous thromboembolic disease. In: Colman R.W., Marder V.J., Clowes A.W., George J.N., and Goldhaber S.J. (Eds). Hemostasis and thrombosis: basic principles and clinical practice. 5th edition (2006), Lippincott, Williams & Wilkins, Philadelphia, PA 1317-1330
2. Wells P.S., and Forster A.J. Thrombolysis in deep vein thrombosis: Is there still an indication?. Thromb Haemost 86 (2001) 499-508
3. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., and Comerota A.J. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edition. Chest 133 (2008) 454S-545S
4. Mewissen M.W., Seabrook G.R., Meissner M.H., Cynamon J., Labropoulos N., and Haughton S.H. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: Report of a National Multicenter Registry. Radiology 211 (1999) 39-49
5. Weinmann E.E., and Salzman. Deep-vein thrombosis. N Eng J Med 331 (1994) 1630-1641
6. O'Meara III J.J., McNutt R.A., Evans A.T., Moore S.W., and Downs S.M. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 330 (1994) 1864-1869
7. Sherry S., Bell W.R., Duckert F.H., Fletcher A.P., Gurewich V., Long D.M., et al. Thrombolytic therapy in thrombosis: a National Institutes of Health Consensus Development Conference. Ann Intern Med 93 (1980) 141-144
8. Kanter D.S., Mikkola K.M., Patel S.R., Parker J.A., and Goldhaber S.Z. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 111 (1997) 1241-1245
9. Ouriel K., Gray B., Clair D.G., and Olin J. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 11 (2000) 295-298
10. Marder V.J. The use of thrombolytic agents: Choice of patient, drug administration, laboratory monitoring. Ann Intern Med 90 (1979) 802-808
11. Ambrus J.L., Ambrus C.M., Back N., Sokal J.E., and Collins G.L. Clinical and experimental studies on fibrinolytic enzymes. Ann NY Acad Sci 68 (1957) 97-110
12. Sherry S., Fletcher A.P., and Alkjaersig N. Fibrinolysis and fibrinolytic activity in man. Physiol Rev 39 (1959) 343-382
13. Douglas A.S., and McNicol G.P. Thrombolytic therapy. Br Med Bull 20 (1964) 228-232
14. Verstraete M., Vermylen J., and Amery A. Enzymatic clot dissolution in man: a new therapeutic approach. Acta Clin Belg 19 (1964) 271-290
15. Marder V.J., Landskroner K., Novokhatny V., Zimmerman T.P., Kong M., Kanouse J.J., et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 86 (2001) 739-745
16. Castellino F.J., and Ploplis V.A. Structure and function of the plasminogen/plasmin system. Thromb Haemost 93 (2005) 647-654
17. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 43 (1980) 77-89
18. Novokhatny V., Taylor K., and Zimmerman T.P. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost 1 (2003) 1034-1041
19. Potter van Loon B.J., Rijken D.C., Brommer E.J., and van der Maas A.P. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 67 (1992) 101-105
20. Önundarson P.T., Haraldsson H.M., Bergmann L., Francis C.W., and Marder V.J. Plasminogen depletion during streptokinase treatment or two chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro. Thromb Haemost 70 (1993) 998-1004
21. Medynski D., Tuan M., Liu W., Wu S., and Lin X. Refolding, purification and activation of miniplasminogen and microplasminogen isolated from E. coli inclusion bodies. Protein Expr Purif 52 (2007) 395-402
22. Hunt J., Petteway S., Scuderi P., and Novokhatny V. Simplified recombinant plasmin: Production and functional comparison of a novel thromobolytic molecule with plasma-derived plasmin. Thromb Haemost 100 (2008) 413-419
23. Castellino F.J., and McCance S.G. The kringle domains of human plasminogen. CIBA Found Symp 212 (1997) 46-60
24. Jones G., Ronk M., Mori F., and Zhang Z. Disulfide structure of alfimeprase: a recombinant analog of fibrolase. Protein Sci 10 (2001) 1264-1267
25. Stewart D., Kong M., Novokhatny V., Jesmok G., and Marder V.J. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 101 (2003) 3002-3007
26. Shlansky-Goldberg R.D., Matsumoto A.H., Baumbach G.A., et al. A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion. J Thromb Haemost 6 (2008) 944-950
27. Comerota A.J. Development of catheter-directed intrathrombus thrombolysis for treatment of peripheral arterial occlusion. Thromb Res 122 Suppl 3 (2008) S20-S26
28. Marder V.J., Shortell C.K., Fitzpatrick P.G., Kim C., and Oxley D. An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. Thromb Res 67 (1992) 31-40
29. Proctor R.R., and Rapaport S.I. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 36 (1961) 212-219
30. Ellis B.C., and Stransky A. A quick and accurate method for the determination of fibrinogen in plasma. J Lab Clin Med 58 (1961) 477-488
31. Friberger P., Knos M., Gustavsson S., Aurell L., and Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 7 (1978) 138-145
32. Shebuski R.J., Storer B.L., and Fujita T. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. Thromb Res 52 (1988) 381-392
33. The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 (1995) 1581-1587
34. Wilcox R.G., von der Lippe G., Olsson C.G., Jensen G., Skene A.M., and Hampton J.R. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: ASSET. Lancet 2 (1988) 525-530
35. Bero C.J., Cardella J.F., Reddy K., Fox P.S., Healy D.A., Jaffe J., et al. Recombinant tissue plasminogen activator for the treatment of lower extremity peripheral vascular occlusive disease. J Vasc Interv Radiol 6 (1995) 571-577
36. Califf R.M., Fortin D.F., Tenaglia A.N., and Sane D.C. Clinical risks of thrombolytic therapy. Am J Cardiol 69 (1992) 12A-20A
37. Heymans S., Vanderschueren S., Verhaeghe R., et al. Outcome and one year follow-up of intra-arterial staphylokinase in 191 patients with peripheral arterial occlusions. Thromb Haemost 83 (2000) 666-671
38. Topol E.J. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357 (2001) 1905-1914
39. Gore J.M., Sloan M., Price T.R., et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Circulation 83 (1991) 448-459
40. Collen D., Topol E.J., Tiefenbrunn A.J., et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: prospective randomized placebo-controlled trial. Circulation 70 (1984) 1012-1017
41. Rao A.K., Pratt C., Berke A., et al. Thrombolysis in MI (TIMI) trial Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11 (1988) 1-11
42. Bovill E.G., Terrin M.L., Stump D.C., et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. Ann Intern Med 115 (1991) 256-265